SynOx reports positive Phase 3 TANGENT results showing short-course emactuzumab delivered rapid tumor reduction and durable functional improvement in TGCT, with BLA planned for 2026.
Written By: Vennela Reddy, BPharm
Reviewed By: Pharmacally Editorial Team
SynOx Therapeutics reported positive topline results from the pivotal Phase 3 TANGENT trial evaluating emactuzumab in adults with tenosynovial giant cell tumor (TGCT), demonstrating statistically significant improvements in tumor reduction and functional outcomes following a defined short-course treatment.
Emactuzumab is a targeted CSF-1R inhibitor designed as a limited-duration therapy to deliver rapid and durable disease control without continuous treatment. In the randomized, placebo-controlled study, patients received emactuzumab 1,000 mg every two weeks for five doses over an eight-week period.
Rapid Tumor and Functional Benefit
The trial met its primary and key secondary endpoints, showing clinically meaningful tumor volume reduction along with improvements in physical function, pain, stiffness, and range of motion. Benefits emerged rapidly during the short-course regimen and were durable across clinically relevant patient groups. Emactuzumab also demonstrated a manageable safety profile consistent with prior clinical experience.
Company and Investigator Perspective
SynOx CEO Dr. Ray Barlow said the results support emactuzumab as a potential next-generation option, highlighting rapid onset, meaningful functional improvement, and a defined short-course regimen as an alternative to chronic therapy. The company plans to engage with the FDA toward a biologics license application in the second half of 2026.
Principal investigator Dr. Jean-Yves Blay noted that the Phase 3 data demonstrate tumor response, manageable safety, and durable functional and quality-of-life improvements without continuous therapy.
Trial Design and Next Steps
The global, randomized, double-blind Phase 3 TANGENT trial (NCT05417789) evaluates emactuzumab in patients with TGCT where surgery may worsen function or carries high recurrence risk. The primary endpoint is objective response rate at six months, with secondary endpoints assessing tumor volume, physical function, pain, stiffness, range of motion, and duration of response. SynOx continues follow-up to assess durability and retreatment potential, with full data planned for presentation at a medical meeting.
Targeting a Debilitating Joint Tumor
TGCT is a rare, locally aggressive tumor affecting synovium and tendon sheaths, most commonly in knee, hip, and ankle joints. The disease causes pain, stiffness, and progressive functional limitation. Current treatment options include surgery and chronic oral therapies, both associated with limitations such as recurrence risk and long-term treatment burden.
Emactuzumab, a high-affinity monoclonal antibody targeting CSF-1R, is designed to block receptor activation, deplete tumor-promoting macrophages, and reduce inflammation in the tumor microenvironment. The therapy has received FDA Fast Track designation and EU orphan status for TGCT. The company intends to submit a BLA to the FDA in the second half of 2026, followed by a European filing.
Reference
About the Writer
Vennela Reddy, B.Pharm is a pharmacy graduate with a keen interest in clinical research, pharmacovigilance, and medical writing, with a growing focus on publishable and scientific content development. In her words, she is passionate about translating complex medical data into clear, evidence-based communication.